Novo Nordisk raises guidance on strong Victoza sales
This article was originally published in Scrip
Executive Summary
Novo Nordisk has posted another strong set of quarterly results, helped by a 25% increase in Victoza (liraglutide) sales. Forecasts for 2013 have now been raised.